Recently, Pfister et al., published highly discussed evidence of lowered effectiveness of immunotherapy in HCC patients than in non-alcoholic steatohepatitis (NASH) patients with HCC due to the presence of special resident-like activated CD8+ cells in patients with NASH [15]. This evidence concerns the gene CD8A and metabolic dysfunction-associated steatohepatitis.